Cargando…
The potential of PARP as a therapeutic target across pediatric solid malignancies
BACKGROUND: Pediatric cancer is the leading cause of disease-related death in children and the need for better therapeutic options remains urgent. Due to the limited number of patients, target and drug development for pediatrics is often supplemented by data from studies focused on adult cancers. Re...
Autores principales: | Keller, Kaylee M., Koetsier, Joost, Schild, Linda, Amo-Addae, Vicky, Eising, Selma, van den Handel, Kim, Ober, Kimberley, Koopmans, Bianca, Essing, Anke, van den Boogaard, Marlinde L., Langenberg, Karin P. S., Jäger, Natalie, Kool, Marcel, Pfister, Stefan, Dolman, M. Emmy M., Molenaar, Jan J., van Hooff, Sander R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077757/ https://www.ncbi.nlm.nih.gov/pubmed/37020198 http://dx.doi.org/10.1186/s12885-022-10319-7 |
Ejemplares similares
-
Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma
por: Keller, Kaylee M., et al.
Publicado: (2022) -
Defects in 8-oxo-guanine repair pathway cause high frequency of C > A substitutions in neuroblastoma
por: van den Boogaard, Marlinde L., et al.
Publicado: (2021) -
Two opposing gene expression patterns within ATRX aberrant neuroblastoma
por: van Gerven, Michael R., et al.
Publicado: (2023) -
MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma
por: Eleveld, Thomas F., et al.
Publicado: (2023) -
Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma
por: George, Sally L, et al.
Publicado: (2020)